<DOC>
	<DOCNO>NCT02630004</DOCNO>
	<brief_summary>The main purpose study assess efficacy melatonin oral gel compare placebo prevention treatment oral mucositis patient head neck cancer undergo concurrent chemoradiation . Other objective assess Quality Life ( QoL ) , evaluate safety tolerability assess pharmacokinetic profile melatonin oral gel administration , case compare placebo patient head neck cancer oral mucositis secondary concurrent chemoradiation .</brief_summary>
	<brief_title>Melatonin Oral Gel Oral Mucositis Patients With Head Neck Cancer Undergoing Chemoradiation</brief_title>
	<detailed_description>The study design prospective , randomize , double blind placebo-controlled study . Eligible patient head neck cancer undergo chemoradiation randomize assign one-to-one ratio receive - Group A : melatonin oral gel 3 % - Group B : placebo All patient receive standard symptomatic treatment oral mucositis along study accord routine clinical practice hospital . A full PK safety assessment carry first 24 patient include study ( PK subgroup ) . All patient take melatonin oral gel 3 % placebo oral gel two three day start systemic treatment one four week completion radiotherapy . In case concurrent chemotherapy cisplatin , patient remain study first day chemoradiotherapy 19 week ( seven chemoradiotherapy treatment , maximum four week completion radiotherapy eight week observation ) . In case patient receive cetuximab , since first infusion cetuximab administer one week first day radiation , patient remain study 20 week ( eight week chemoradiotherapy , maximum four week completion radiotherapy eight week observation ) . Investigators take account minimum duration melatonin oral gel 3 % treatment would 8 week patient treat cisplatin 9 week patient treat cetuximab . Patients oral mucositis improve grade 1 ( base RTOG ) one four week end chemoradiation may stop melatonin oral gel 3 % placebo treatment . Patients grade ≥ 2 oral mucositis time-point ( four week end chemoradiation ) stop treatment per protocol ( melatonin placebo ) continue standard treatment observation last safety visit .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>1 . Male female patient 18 year . 2 . Patients give write informed consent . 3 . Life expectancy ≥ 3 month . 4 . Subjects willing comply treatment followup . 5 . Histologically confirm diagnosis nonmetastatic TNM2010 stage IIIIV squamous cell carcinoma follow site : oral cavity oropharynx Head Neck site lymph nodes cervical level II . Or histologically confirm carcinoma nasopharynx ( differentiate squamous cell carcinoma NonKeratinizing carcinoma undifferentiated carcinoma ) find eligible chemoradiation without neoadjuvant chemotherapy . 6 . Patients treatment plan base systemic treatment ( cisplatin cetuximab ) concurrent radiation curative intent . Patients may receive 3 cycle neoadjuvant chemotherapy local adverse event related treatment fully resolve study entry . Patients plan postoperative chemoradiation may include primary tumour locate oral cavity . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 8 . Adequate baseline organ function ( hematologic , liver , renal , nutritional metabolic ) : Haematology : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Haemoglobin ≥ 10 g/dL Platelets ≥ 100,000 x 109/L Hepatic : Total bilirubin ≤ 2 X ( Upper limit normal ) ULN Alanine amino transferase ( ALT ) Asparatate aminotransferase ( AST ) ≤5 x ULN Renal : For patient receive cisplatin : Serum creatinine ≤ ULN , &gt; ULN calculate creatinine clearance ( ClCR ) ≥ 60 mL/min . For patient receive cetuximab : Serum creatinine &lt; 2.0 mg/dl . Nutritional metabolic : Albumin &gt; 3.0 mg/dl Magnesium &gt; low limit normal ( LLN ) patient receive cetuximab 1 . Patients blister disease . 2 . Patients require feed either nasogastric tube , gastrostomy jejunostomy study entry 3 . Patients whose radiotherapy treatment plan dose low 66 Gy 4 . Patients receive another investigational agent participation another therapeutic trial 5 . Patients treated fluvoxamine , estrogens , cimetidine , 5 8 methoxypsoralen and/or carbamazepine 6 . Active viral , bacterial fungal infection mouth last 14 day ( i.e . stomatitis related herpes virus candida ) 7 . Pregnancy lactation 8 . Known allergy melatonin 9 . Prior radiotherapy head neck 10 . Patients treatment plan consist chemoradiation follow chemotherapy 11 . Patients diagnostics synchronic neoplasia except nonmelanoma skin cancer curable local treatment situ cervix carcinoma 12 . Any investigational agent within 30 day prior inclusion 13 . Male female childbearing age agree take adequate contraceptive precaution , i.e . use contraception double barrier ( e.g . diaphragm plus condom ) abstinence course study 2 month last administration study drug woman 1 month men 14 . Psychological , geographical , familial sociological condition potentially prevent compliance study protocol followup schedule accord investigator criterion . These condition discuss patient inclusion trial . 15 . Any medical condition would make patient inappropiate study participation accord Investigator 's judgement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mucositis</keyword>
	<keyword>Head Neck cancer</keyword>
	<keyword>Chemoradiation</keyword>
</DOC>